| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.17 | 0.001 |
| mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | AS605240 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.002 |
| mRNA | GW843682X | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | FR-180204 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.002 |
| mRNA | PD318088 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | TAE684 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.11 | 0.002 |